Throwback from 2008. Some physicians understood the dangers Reclast represented. Dr. Javad Parvizi Joint Specialist and Director of Orthopaedic Research Rothman Institute at Thomas Jefferson University Hospital Philadelphia, Pa. I dont think we should anticipate FDA regulations, but if approved, the use of this medication should be reserved to a limited population without heart conditions and severe or refractory osteoporosis. Dr. Lawrence Raisz Director The University of Connecticut Center for Osteoporosis Hartford, Conn. The issue of atrial fibrillation is important and will mean the patients need to be warned and monitored. J. Edward Puzas Professor of Orthopaedics University of Rochester School of Medicine and Dentistry Rochester, N.Y. Most experts feel that this drug will provide a new approach to treating patients. The ability to administer a medication once a year to patients will increase compliance and ensure that a person gets the appropriate dose. The data show no serious adverse effects over placebos, but until the medication is in widespread use, it is difficult to tell if there are any problems — just look at the issues with Vioxx. abcnews.go/Health/WomensHealth/story?id=3132172&page=1&singlePage=true
Posted on: Fri, 29 Aug 2014 04:17:33 +0000
Trending Topics
Recently Viewed Topics
© 2015